[COR] Cencora: Fiscal Q4 2026 Earnings Test Oncology MSO Profit Growth

Cencora (COR) is one of the main U.S. drug wholesalers, distributing branded, generic and specialty drugs to pharmacies, health systems and specialty physician practices, and it also runs oncology and other specialty practices through management services organizations (MSOs)[1][2]. Ahead of Cencora's fiscal Q4 2026 earnings, the company is scheduled to report results and hold its call on 2026-11-04 for the Fourth quarter fiscal 2026 (three months ended September 30, 2026)[3][4]. In the latest disclosed period, the fiscal third quarter ended June 30, 2026, revenue was $84.8 billion, up 5.1% year over year, adjusted diluted EPS was $4.48, up 12.0%, and U.S. Healthcare Solutions segment operating income was $966.2 million, up 15.9%[2]. Cencora does not give quarterly guidance, but on October 21 it raised fiscal 2026 adjusted diluted EPS guidance to at least $17.90[4]; against first-three-quarter adjusted EPS of $4.08, $4.75 and $4.48, or $13.31 in total[5][6], the fourth quarter needs at least $4.59. Six analysts compiled by Drillr put fourth-quarter consensus EPS at $4.58 (range $4.46 to $4.64) and consensus revenue at about $87.95 billion, while seven analysts put full-year consensus EPS at $17.89; these figures may not yet fully reflect the October 21 guidance update[7].

Three things matter most in these results. The first is U.S. segment profit: guidance for 14.5% to 15.5% full-year segment operating income growth[2] implies roughly $964 million to $997 million in the fourth quarter, and management said that, excluding OneOncology and a lost oncology customer, organic operating income growth accelerated in the third quarter from 7% in the second quarter to double digits[8], so the fourth quarter tests whether that acceleration holds. The second is U.S. segment revenue: third-quarter GLP-1 sales rose $2.3 billion year over year while manufacturer list-price cuts on branded drugs created about $2.4 billion of headwind[8], nearly cancelling out, so whether fourth-quarter revenue growth stays above 3% sets the starting point for fiscal 2027. The third is cash: operating cash flow was only $1.69 billion through nine months and total debt reached $11.72 billion at the end of June[9], against full-year adjusted free cash flow guidance of about $3.0 billion[2], so fourth-quarter collections determine how much new borrowing the AON and other deals require; the company will also discuss its fiscal 2027 expectations for the first time on the same call[4].

Company Background and Business Structure

Cencora is a wholesaler whose revenue is mostly the value of drugs passing through its hands and whose profit comes from thin spreads, and it is typically the primary source of supply for its healthcare provider customers[1]. Its fiscal year ends on September 30, and fiscal 2025 consolidated revenue was $321.3 billion[2]. Its manufacturer customers include branded, generic and biotechnology drug makers, while its downstream customers span pharmacies, health systems and physician practices[1].

The company has two reportable segments plus a group of businesses reported as Other, and most of its profit comes from the United States. U.S. Healthcare Solutions generated about $285.0 billion of fiscal 2025 revenue and $3.283 billion of segment operating income[2][1], and beyond drug distribution it takes part in running specialty practices through two MSOs, RCA, acquired in January 2025, and OneOncology, in which it took majority control in February 2026[5]; total fair value consideration for OneOncology was $7,387.1 million, including $4,648.7 million in cash[9]. International Healthcare Solutions generated about $28.3 billion of fiscal 2025 revenue and $588 million of operating income[2], and it includes the European drug distributor Alliance Healthcare and the global specialty logistics company World Courier[1]. Other generated about $8.2 billion of revenue and $352 million of operating income and consists of businesses for which the company is exploring strategic alternatives, including MWI Animal Health and Brazil's Profarma[2], and MWI plans to merge with Covetrus[8].

Customer concentration is high, and working capital rests largely on supplier payment terms. In fiscal 2025 the top 10 customers represented about 66% of revenue, with Walgreens and Boots together about 25% and Evernorth Health Services about 13%; at September 30, 2025, Walgreens and Boots represented about 38% of net accounts receivable[1]. In the same year days payable outstanding were 59.6, more than the sum of 27.9 days sales outstanding and 27.0 days of inventory on hand, which means suppliers largely fund the working capital needed for growth[1].

Financial History and Current Position

Fiscal 2025 was a year in which both revenue and segment profit expanded. Revenue rose $27.4 billion, or 9.3%, with U.S. segment revenue up 9.7% and GLP-1 product sales up $7.7 billion, or 26.9%[1]. Total segment operating income rose from $3.289 billion in fiscal 2023 and $3.648 billion in fiscal 2024 to $4.223 billion in fiscal 2025, while the U.S. segment rose from $2.315 billion to $3.283 billion over the same period[1]. On the company's basis, fiscal 2025 adjusted diluted EPS was $16.00 and adjusted free cash flow was $3.0 billion[2]; GAAP net income was about $1.6 billion including $837.4 million of asset impairments, and operating cash flow was about $3.9 billion, driven mainly by a $3.7 billion increase in accounts payable[1].

In the first three quarters of fiscal 2026, profit grew much faster than revenue. Quarterly revenue was $85.9 billion, $78.4 billion and $84.8 billion, up 5.5%, 3.8% and 5.1%, while adjusted diluted EPS was $4.08, $4.75 and $4.48 against $3.73, $4.42 and $4.00 a year earlier[5][6][2]. In the third quarter adjusted gross profit was $3.5 billion, up 23.2%, adjusted operating expenses were $2.3 billion, up 26.8%, adjusted operating income was about $1.2 billion, up 17.0%, and diluted shares were 193.9 million, down 0.7%[2]. Over nine months, U.S. segment operating income was $2,795.8 million, up 13.4%, and International was $483.8 million, up 5.9%[9].

After the OneOncology acquisition the balance sheet became clearly more leveraged. Total debt rose from $7,660.8 million at September 30, 2025 to $11,723.2 million at June 30, 2026, nine-month operating cash flow was $1,687.5 million versus $741.7 million a year earlier, and capital expenditures were $511.0 million[9]. Third-quarter net interest expense was $140.7 million, up $58.9 million from a year earlier, and full-year net interest guidance is about $490 million against $292 million in fiscal 2025[2]. In the third quarter the company repurchased $1 billion of stock at an average of $268 per share and has fully repaid its $800 million RCA-related term loan[8].

Operating Model

Revenue is driven mainly by unit volume and drug list prices rather than by the company's own margins. Revenue can be read as each customer group's unit volume times drug list prices, plus service fees and MSO practice revenue: volume growth in specialty drugs and GLP-1s pushes revenue up, while manufacturer list-price cuts on branded drugs, customer losses and brand conversions at large customers push it down[9]. In the third quarter U.S. segment revenue rose $3.5 billion to $74.9 billion, with GLP-1s adding $2.3 billion and list-price cuts creating about $2.4 billion of headwind[9][8], and these factors show up in revenue in the same quarter the products ship.

Profit depends on changes in gross margin mix, not just on revenue scale. Gross profit comes from thin distribution spreads, manufacturer service fees and specialty and MSO service margins, and consolidated adjusted gross margin is only about 4%: it was 4.16% in the third quarter, up 61 basis points, and 4.31% in the second quarter, up 45 basis points, with both gains driven mainly by OneOncology, consolidated from February 2026, and partly offset by lower-margin GLP-1s[2][6]. Acquisition-driven margin gains appear in year-over-year comparisons from the quarter of consolidation; after operating expenses of about 2.7% of revenue, third-quarter total segment operating income was $1,238.1 million, about 1.46% of revenue[9]. Subtracting full-year net interest of about $490 million and an adjusted tax rate of about 20%, then dividing by about 194 million shares, gives adjusted diluted EPS[2].

Cash flow depends on the timing of quarter-end working capital and swings sharply between quarters. Because supplier terms are longer than the collection and inventory cycle, a larger business usually generates cash[1]; according to Drillr financial data, fiscal 2025 operating cash flow was $3.875 billion, and subtracting the $741.7 million generated in the first nine months[9] leaves about $3.133 billion in the fourth quarter, roughly 80% of the year. Cash goes to capital expenditures (about $900 million guided for fiscal 2026), shareholder returns and MSO acquisitions, with borrowing covering any shortfall[2].

Industry and Competitive Position

U.S. drug wholesaling is dominated by Cencora, McKesson and Cardinal Health, and competition centers on large customer contracts, purchasing scale and specialty capabilities. Cencora's customer base is highly concentrated, with Walgreens and Boots plus Evernorth accounting for about 38% of revenue[1], so changes at large customers flow directly into growth, as when brand conversions at a large mail-order customer weighed on fiscal second-quarter 2026 revenue[6].

Cencora's relative strength is in specialty drugs, and it is extending that strength into running physician practices. Third-quarter U.S. growth came mainly from specialty utilization across health systems and physician practices, operating income growth was led by MSOs, health systems and community provider businesses, and both OneOncology and RCA outperformed the company's expectations[8]. On October 21 the company agreed to acquire American Oncology Network (AON), a network of more than 350 oncology providers across 21 states that adds twelve states to its footprint[4]; its long-term guidance calls for 7% to 10% annual adjusted operating income growth and 10% to 14% annual adjusted diluted EPS growth[10]. The available disclosures do not include peers' segment profit data, so the specialty profit gap between Cencora and McKesson or Cardinal Health cannot be quantified.

Core Debates

With OneOncology fully consolidated and the lost oncology customer lapped, can U.S. Healthcare Solutions deliver the roughly $964-997 million of fourth-quarter operating income implied by guidance, with organic growth still in double digits?

This question decides whether profit from the specialty and MSO strategy is being stacked up through acquisitions or whether the core business itself is accelerating. The U.S. segment earned $3.283 billion of operating income in fiscal 2025, about 78% of the $4.223 billion segment total[1]. On October 21 the company cited U.S. segment strength in raising full-year adjusted diluted EPS guidance to at least $17.90[4]; with $13.31 earned in the first three quarters, the fourth quarter needs at least $4.59, about 19% above roughly $3.85 a year earlier[2].

Third-quarter data show U.S. segment profit growing far faster than revenue. Segment revenue was $74.9 billion, up 4.9%, and operating income was $966.2 million, up 15.9% from $833.7 million, bringing the nine-month total to $2,795.8 million[9]. Subtracting nine-month operating income of $2,465.5 million from the fiscal 2025 total of $3,283.4 million puts last year's fourth-quarter base at about $817.9 million[1][9], so guidance for 14.5% to 15.5% full-year growth[2] implies roughly $964 million to $997 million in the fourth quarter. Management said organic operating income growth, excluding OneOncology and the lost oncology customer, accelerated from 7% in the second quarter to double digits, and that the fourth quarter would bring the strongest U.S. organic growth of the year, but it did not disclose a specific figure[8].

The profit chain starts with specialty utilization and ends in EPS. Specialty drug use in health systems and physician practices, plus MSO practice service revenue, lifts U.S. segment gross margin so that segment operating income grows far faster than revenue, which then flows into adjusted operating income and adjusted diluted EPS; third-quarter consolidated adjusted gross margin was 4.16%, up 61 basis points[2]. What remains unresolved is the nature of the acceleration: management attributed part of the raised segment guidance to "easier year-over-year expense comparisons in Q4"[8], and the third-quarter acceleration may partly reflect specialty utilization catching up between quarters, both of which would make profit growth overstate the improvement in underlying demand.

Three numbers need to be read together in the fourth quarter. The first is whether U.S. segment operating income lands between $964 million and $997 million or higher, the second is whether management confirms double-digit organic operating income growth for the quarter, and the third is whether year-over-year adjusted gross margin expansion stays at 45 basis points or more, along with fiscal 2027 U.S. segment profit growth guidance. If U.S. segment operating income falls below $964 million, or organic growth drops back to single digits, the third-quarter acceleration was mainly a one-time catch-up and the current understanding needs revising.

Can GLP-1 volume keep offsetting brand list-price cuts and lower sales to large customers, holding fourth-quarter U.S. segment revenue growth inside the implied 3%-7% range?

Revenue growth sets the company's scale, its bargaining position with customers and the starting point for fiscal 2027 guidance. Nearly all of Cencora's revenue is the pass-through value of drugs: fiscal 2025 consolidated revenue was $321.3 billion, while adjusted operating income was only about $4.2 billion[2]. Fiscal 2026 consolidated revenue growth guidance was cut from 7% to 9% in February[11] to 4% to 6% in May[12], reflecting branded list-price cuts and brand conversions at a large mail-order customer[6].

Third-quarter revenue was the result of growth and headwinds nearly cancelling out. U.S. segment revenue was $74.9 billion, up 4.9% or $3.5 billion, and nine-month revenue rose 4.3% or $9.1 billion; GLP-1 sales rose $2.3 billion, or 25.5%, in the quarter and $5.2 billion, or 19.7%, over nine months[9]. At the same time, manufacturer list-price cuts on branded drugs created about $2.4 billion of headwind, alongside the 2025 loss of an oncology customer and lower sales to a large mail-order customer[8]. Second-quarter U.S. segment revenue was $68.8 billion, up about 3%[12], and management expects full-year U.S. revenue growth in the lower half of the 4% to 6% range[8].

Revenue changes affect profit far less than they affect revenue itself. Because distribution spreads are thin, list-price cuts and customer mix shifts mainly reduce revenue and have limited effect on gross profit, while a rising GLP-1 share actually dilutes gross margin[2]. An alternative reading therefore holds that slower revenue does not by itself signal a weaker business, since U.S. segment operating income rose 15.9% in the same quarter[9]; the real risk to watch is a change in contract terms with Walgreens (about 25% of revenue) or Evernorth (about 13% of revenue)[1]. What remains unresolved is whether the list-price headwind widens further in the fourth quarter.

The fourth quarter should be read through revenue growth, GLP-1 growth and the company's explanation of the list-price headwind. Specifically, the questions are whether U.S. segment revenue growth is at least 3%, whether GLP-1 sales growth stays around 20%, and how the company quantifies the branded list-price headwind and sets fiscal 2027 revenue guidance. If U.S. segment revenue growth falls below 3%, price and customer headwinds are widening; if GLP-1 growth drops below 10%, revenue loses its main growth source.

With only $1.69 billion of operating cash flow through nine months, can fourth-quarter collections lift fiscal 2026 adjusted free cash flow to about $3 billion and leave room to fund the AON and EyeSouth deals?

Drug distributors run on supplier credit, so cash flow is highly sensitive to quarter-end timing, and Cencora's funding needs have grown markedly this year. The company paid $4,648.7 million in cash for OneOncology in February 2026, total debt rose from $7,660.8 million to $11,723.2 million[9], and it repurchased $1 billion of stock in the third quarter[8]; in October it agreed to pay about $1.7 billion to raise its AON stake to 75% in a deal with an enterprise value of $2.4 billion[4]. Another retina-practice acquisition, EyeSouth (written as I-South Retina in the call summary), has no updated closing timeline, and management advised against including it in 2027 models[8].

The cash baseline depends on how much flows back in the fourth quarter. Operating cash flow for the first nine months of fiscal 2026 was $1,687.5 million, up from $741.7 million a year earlier, with capital expenditures of $511.0 million[9]; based on full-year operating cash flow of $3.875 billion in Drillr financial data, last year's fourth quarter generated about $3.133 billion, roughly 80% of the year. The company reaffirmed full-year adjusted free cash flow of about $3.0 billion and fully repaid the RCA term loan in July[8].

The cash chain ultimately runs into debt, interest and EPS. The timing of quarter-end receivables, inventory and payables determines fourth-quarter operating cash flow, which determines adjusted free cash flow, which in turn funds debt repayment, buybacks and MSO acquisitions, and the result shows up in quarter-end total debt, full-year net interest of about $490 million and adjusted diluted EPS[2]; in fiscal 2025 days payable exceeded days receivable plus inventory by about 4.7 days[1]. An alternative reading is that the stronger nine-month figure came mainly from payment timing, which could shrink the seasonal fourth-quarter inflow, and that growth in high-priced drugs such as GLP-1s ties up more inventory and receivables.

The fourth quarter should be read through free cash flow, quarter-end debt and deal funding. Specifically, the questions are whether fiscal 2026 adjusted free cash flow reaches about $3.0 billion, whether total debt at September 30 is below the $11,723.2 million of June 30, and how fiscal 2027 guidance handles the timing and funding of AON, EyeSouth and the MWI-Covetrus merger; management's modeling reference is that if the MWI merger with Covetrus closes at the midpoint of fiscal 2027, Other segment operating income would fall by about $150 million and EPS would take a net hit of about $0.35[8]. If full-year adjusted free cash flow comes in below $2.5 billion, or quarter-end debt keeps rising while the deals remain unclosed, the current understanding weakens.

Risks and Falsifiers

Customer concentration is the most direct risk to revenue and cash. Walgreens and Boots together accounted for about 25% of fiscal 2025 revenue and 38% of net accounts receivable at September 30, 2025, Evernorth about 13% of revenue, and the top 10 customers about 66% of revenue[1]; a contract expiry, worse renewal terms or a customer's financial deterioration would hit revenue and cash at the same time. If major customer contracts renew on schedule without worse terms, and no new large-customer loss is disclosed in the fourth quarter, this risk has not materialized.

Policy changes could weaken the base for specialty and MSO growth. On the third-quarter call management said proposed updates to 340B drug pricing rules and changes to ASP reimbursement for Part B therapies under the Inflation Reduction Act carry uncertainty[8], and these could reduce reimbursement for community oncology practices and in turn MSO and specialty distribution demand. The exposed profit is the U.S. segment's $3.283 billion of fiscal 2025 operating income[1] and the $4,648.7 million of cash paid for OneOncology[9]; if final rules leave community physician reimbursement unchanged, this risk is falsified.

Quarter-to-quarter swings in specialty utilization or slower MSO physician recruitment could pull U.S. segment profit growth back to single digits outside acquisition contributions. The U.S. segment accounts for about 78% of total segment operating income[1], and guidance implies about $964 million to $997 million of fourth-quarter segment operating income[2]. If fourth-quarter U.S. segment operating income is at least $964 million and management confirms double-digit organic growth, this concern does not hold.

Further branded list-price cuts or government price negotiations taking effect would keep shrinking pass-through revenue and could compress distribution fees tied to list prices. List-price cuts already created about $2.4 billion of quarterly revenue headwind in the third quarter[8], against fiscal 2025 U.S. segment revenue of about $285.0 billion[2]. If fourth-quarter U.S. segment revenue growth is at least 3% and the list-price headwind does not exceed about $2.4 billion, this risk remains within known bounds.

Serial MSO acquisitions push up debt and interest while the returns arrive later. Total debt was $11,723.2 million at June 30[9], and fiscal 2026 net interest is about $490 million versus $292 million a year earlier[2]; AON requires about $1.7 billion in cash, and the company said the deal will add to adjusted diluted EPS only in the second year after closing[4]. If fiscal 2026 adjusted free cash flow is at least $3.0 billion and total debt at September 30 is no higher than $11,723.2 million, this risk eases for now.

What to Watch Next

• Specialty and MSO profit: fourth-quarter U.S. segment operating income against a third-quarter base of $966.2 million (up 15.9%) and a prior-year fourth quarter of about $817.9 million; reaching $964 million to $997 million supports the current reading, while anything below $964 million weakens it.
• Organic growth: whether management confirms fourth-quarter organic operating income growth in double digits, after 7% in the second quarter and double digits in the third; a drop to single digits would point to a one-time catch-up.
• Gross margin: whether year-over-year adjusted gross margin expansion stays at 45 basis points or more, after 4.16% and 61 basis points in the third quarter.
• Revenue volume and price: whether U.S. segment revenue growth is at least 3% after $74.9 billion and 4.9% in the third quarter, and whether GLP-1 growth stays near 20% after a $2.3 billion, 25.5% gain; GLP-1 growth below 10% would remove the main growth source.
• Cash and deals: whether fiscal 2026 adjusted free cash flow reaches about $3.0 billion (below $2.5 billion weakens the reading), whether September 30 total debt falls from $11,723.2 million, and how fiscal 2027 guidance times and funds AON, EyeSouth and the MWI merger.

Conclusion

Cencora's profit increasingly depends on specialty drugs and physician management services organizations rather than on its enormous drug pass-through revenue. Fiscal 2025 revenue of $321.3 billion produced only about $4.2 billion of adjusted operating income[2], and in the fiscal 2026 third quarter U.S. segment operating income rose 15.9% while revenue rose only 4.9%[9], a gap driven mainly by the gross margin lift from consolidating OneOncology[2]. At the same time total debt has climbed to $11.72 billion[9], and the company is pursuing further MSO deals such as AON[4]. The central unresolved relationship is whether the acceleration in specialty profit can persist beyond acquisition contributions, and whether fourth-quarter cash inflows can support this acquisition path without a marked increase in debt.

Outside interpretations published after the latest results center on the October 21 AON acquisition, and the two views point in different directions without contradicting each other. According to Reuters, Evercore ISI analyst Elizabeth Anderson said the deal diversifies Cencora's community oncology presence because AON focuses on smaller oncology practices while OneOncology emphasizes larger ones[13], which supports the positive reading of the first debate: MSO expansion reaches a new group of practices rather than duplicating an existing investment. Barclays analyst Glen Santangelo said the deal's size suggests a continuation of the current strategy rather than anything transformational; the same report noted that Cencora shares fell 4.84% to $325.50 within hours of the announcement[14], which matches the third debate's market concern about serial acquisitions and capital use. Both are brief comments quoted in news coverage rather than full research reports, so they serve only as outside interpretations and do not represent a market consensus.

From here, the combination that would materially strengthen the current understanding is fourth-quarter U.S. segment operating income of at least $964 million with confirmed double-digit organic growth, U.S. segment revenue growth above 3%, full-year adjusted free cash flow of about $3.0 billion, and September 30 total debt back below $11,723.2 million. Conversely, if U.S. segment profit falls below the low end implied by guidance, organic growth returns to single digits, and free cash flow comes in below $2.5 billion while debt keeps rising, that would indicate the specialty profit acceleration came more from acquisitions and one-time factors and that serial deals are eating into balance sheet capacity.

Sources

[1] COR FY2025 10-K filed 2025-11-25 · 2025-11-25 · 10-K · https://www.sec.gov/Archives/edgar/data/1140859/000114085925000131/

[2] COR Q3 FY2026 earnings release (8-K) filed 2026-08-05 · 2026-08-05 · 8-K · https://www.sec.gov/Archives/edgar/data/1140859/000114085926000032/

[3] COR earnings calendar updated 2026-10-29 · 2026-10-29 · Drillr earnings calendar

[4] COR 8-K filed 2026-10-21 (AON merger and updated FY2026 expectations) · 2026-10-21 · 8-K · https://www.sec.gov/Archives/edgar/data/0001140859/000110465926117576/tm2627778d1_ex99-1.htm

[5] COR Q1 FY2026 earnings release (8-K) filed 2026-02-04 · 2026-02-04 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001140859&type=8-K&dateb=&owner=include&count=40

[6] COR Q2 FY2026 earnings release (8-K) filed 2026-05-06 · 2026-05-06 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001140859&type=8-K&dateb=&owner=include&count=40

[7] Drillr analyst estimates COR Q4 FY2026 retrieved 2026-10-29 · 2026-10-29 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[8] COR Q3 FY2026 earnings call 2026-08-05 · 2026-08-05 · earnings-call · https://gateway.drillr.ai/mcp/private

[9] COR Q3 FY2026 10-Q filed 2026-08-05 · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1140859/000114085926000034/

[10] COR 8-K filed 2026-05-29 (CFO appointment and guidance reaffirmation) · 2026-05-29 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001140859&type=8-K&dateb=&owner=include&count=40

[11] COR Q1 FY2026 earnings call 2026-02-04 · 2026-02-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[12] COR Q2 FY2026 earnings call 2026-05-06 · 2026-05-06 · earnings-call · https://gateway.drillr.ai/mcp/private

[13] Evercore ISI Elizabeth Anderson view via Reuters 2026-10-21 · 2026-10-21 · Evercore ISI(Reuters 报道) · https://www.ksl.com/article/51639103/cencora-to-acquire-american-oncology-network-in-24-billion-deal

[14] Barclays Glen Santangelo view via Reuters 2026-10-21 · 2026-10-21 · Barclays(Reuters 报道) · https://www.ksl.com/article/51639103/cencora-to-acquire-american-oncology-network-in-24-billion-deal